<DOC>
	<DOCNO>NCT00541723</DOCNO>
	<brief_summary>To investigate efficacy safety incobotulinumtoxinA ( Xeomin ) comparison placebo treatment moderate severe lateral periorbital wrinkle maximum smile compare two different application scheme Xeomin . Each subject treat right left eye area , use dose different application scheme ( i.e . 3 4 injection site ) .</brief_summary>
	<brief_title>Efficacy Safety NT 201 Treatment Lateral Periorbital Wrinkles</brief_title>
	<detailed_description>Conducted Europe</detailed_description>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<criteria>Main Moderate ( grade 2 ) severe ( grade 3 ) symmetrical lateral periorbital wrinkle assess investigator accord 4point scale maximum smile Main Significant facial asymmetry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>